Advertisement

Clinicopathological Analysis of Lymphatic Vessels and of Lymphangiogenesis in Human Cancer

Chapter
  • 513 Downloads
Part of the Cancer Metastasis – Biology and Treatment book series (CMBT, volume 13)

Abstract

Novel prognostic factors are needed to enhance identification of those patients with early-stage node-negative cancer that are at increased risk for relapse and should be considered for adjuvant treatment. Lymphatic invasion, lymphatic vessel density and lymphatic growth factor expression have been proposed as reliable prognostic indicators for several human malignancies. However, controversy concerning the precise role of lymphangiogenesis-associated parameters in predicting patients’ outcome still exists and this is mainly due to differences in patient selection and applied methodology and to the lack of standardization. In this chapter, we provide an overview of the current applied techniques for evaluating tumor lymphangiogenesis in solid human tumors and discuss the biological relevance of lymphangiogenesis for progression of different human malignancies.

Key words

Lymphangiogenesis Lymphangiogenic growth factor Lymphatic vessel density Lymph node metastasis Prognosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Achen MG, Williams RA, Baldwin ME, et al. The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer. Growth Factors 2002, 20: 99–107.PubMedCrossRefGoogle Scholar
  2. 2.
    Achen MG, Williams RA, Minekus MP, et al. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J Pathol 2001, 193: 147–54.PubMedCrossRefGoogle Scholar
  3. 3.
    Adachi Y, Nakamura H, Kitamura Y, et al. Lymphatic vessel density in pulmonary adenocarcinoma immunohistochemically evaluated with anti-podoplanin or anti-D2-40 antibody is correlated with lymphatic invasion or lymph node metastases. Pathol Int 2007, 57: 171–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Agarwal B, Saxena R, Morimiya A, Mehrotra S, Badve S. Lymphangiogenesis does not occur in breast cancer. Am J Surg Pathol 2005, 29: 1449–55.PubMedCrossRefGoogle Scholar
  5. 5.
    Akagi K, Ikeda Y, Miyazaki M, et al. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer 2000, 83: 887–91.PubMedCrossRefGoogle Scholar
  6. 6.
    Akahoshi K, Chijiiwa Y, Hamada S, et al. Endoscopic ultrasonography: a promising method for assessing the prospects of endoscopic mucosal resection in early gastric cancer. Endoscopy 1997, 29: 614–19.PubMedCrossRefGoogle Scholar
  7. 7.
    Al Mowallad A, Kirwan C, Byrne G, et al. Vascular endothelial growth factor-C in patients with breast cancer. In Vivo 2007, 21: 549–51.Google Scholar
  8. 8.
    Alexander-Sefre F, Singh N, Ayhan A, et al. Detection of tumour lymphovascular space invasion using dual cytokeratin and CD31 immunohistochemistry. J Clin Pathol 2003, 56: 786–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Arinaga M, Noguchi T, Takeno S, et al. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 2003, 97: 457–64.PubMedCrossRefGoogle Scholar
  10. 10.
    Audet N, Beasley NJ, MacMillan C, et al. Lymphatic vessel density, nodal metastases, and prognosis in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2005, 131: 1065–70.PubMedCrossRefGoogle Scholar
  11. 11.
    Auvinen MI, Sihvo EI, Ruohtula T, et al. Incipient angiogenesis in Barrett’s epithelium and lymphangiogenesis in Barrett’s adenocarcinoma. J Clin Oncol 2002, 20: 2971–79.PubMedCrossRefGoogle Scholar
  12. 12.
    Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19: 3635–48.PubMedGoogle Scholar
  13. Baldewijns MM, Roskams T, Ballet V, et al. A low frequency of lymph node metastasis in clear-cell renal cell carcinoma is related to low lymphangiogenic activity. BJU Int 2009, Jan 12. [Epub ahead of print]Google Scholar
  14. 14.
    Bando H, Brokelmann M, Toi M, et al. Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues. Int J Cancer 2004, 111: 184–91.PubMedCrossRefGoogle Scholar
  15. 15.
    Bando H, Weich HA, Horiguchi S, et al. The association between vascular endothelial growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: a study with 193 cases. Oncol Rep 2006, 15: 653–9.PubMedGoogle Scholar
  16. 16.
    Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999, 144: 789–801.PubMedCrossRefGoogle Scholar
  17. 17.
    Beasley NJP, Prevo R, Banerji S, et al. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 2002, 62: 1315–20.PubMedGoogle Scholar
  18. 18.
    Birner P, Schindl M, Obermair A, et al. Lymphatic microvessel density as a novel prognostic factor in early-stage invasive cervical cancer. Int J Cancer 2001, 95: 29–33.PubMedCrossRefGoogle Scholar
  19. 19.
    Bono AV. The global state of prostate cancer: epidemiology and screening in the second millennium. BJU Int 2004, 94 Suppl 3: 1–2.PubMedCrossRefGoogle Scholar
  20. 20.
    Bono P, Wasenius VM, Heikkila P, et al. High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin Cancer Res 2004, 10: 7144–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Bonsib SM. The renal sinus is the principal invasive pathway: a prospective study of 100 renal cell carcinomas. Am J Surg Pathol 2004, 28: 1594–600.PubMedCrossRefGoogle Scholar
  22. 22.
    Bonsib SM. Renal lymphatics, and lymphatic involvement in sinus vein invasive (pT3b) clear cell renal cell carcinoma: a study of 40 cases. Mod Pathol 2006, 19: 746–53.PubMedCrossRefGoogle Scholar
  23. 23.
    Bonsib SM, Gibson D, Mhoon M, Greene GF. Renal sinus involvement in renal cell carcinomas. Am J Surg Pathol 2000, 24: 451–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Breiteneder-Geleff S, Matsui K, Soleiman A, et al. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 1997, 151: 1141–52.PubMedGoogle Scholar
  25. 25.
    Cannistra SA. Cancer of the ovary. N Engl J Med 1993, 329: 1550–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Charoenrat P, Rhys-Evans P, Eccles SA. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer 2001, 92: 556–68.CrossRefGoogle Scholar
  27. 27.
    Chen F, Takenaka K, Ogawa E, et al. Flt-4-positive endothelial cell density and its clinical significance in non-small cell lung cancer. Clin Cancer Res 2004, 10: 8548–53.PubMedCrossRefGoogle Scholar
  28. 28.
    Cheng L, Jones TD, Lin H, et al. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. J Urol 2005, 174: 2181–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Choi WW, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 2005, 18: 143–52.PubMedCrossRefGoogle Scholar
  30. 30.
    Creasman WT, Kohler MF. Is lymph vascular space involvement an independent prognostic factor in early cervical cancer? Gynecol Oncol 2004, 92: 525–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Dadras SS, Lange-Asschenfeldt B, Velasco P, et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol 2005, 18: 1232–42.PubMedCrossRefGoogle Scholar
  32. 32.
    Dadras SS, Paul T, Bertoncini J, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003, 162: 1951–60.PubMedGoogle Scholar
  33. 33.
    de la Torre NG, Buley I, Wass JA, Turner HE. Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocr Relat Cancer 2006, 13: 931–44.PubMedCrossRefGoogle Scholar
  34. 34.
    Deans GT, Parks TG, Rowlands BJ, Spence RA. Prognostic factors in colorectal cancer. Br J Surg 1992, 79: 608–13.PubMedCrossRefGoogle Scholar
  35. 35.
    Delgado G, Bundy B, Zaino R, et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1990, 38: 352–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Ding MX, Li JC, Tang XH. [Lymphatic metastasis and VEGF-C expression in ovarian epithelial tumors]. Shi Yan Sheng Wu Xue Bao 2003, 36: 445–52.PubMedGoogle Scholar
  37. 37.
    Ding MX, Lin XQ, Fu XY, Zhang N, Li JC. Expression of vascular endothelial growth factor-C and angiogenesis in esophageal squamous cell carcinoma. World J Gastroenterol 2006, 12: 4582–85.PubMedGoogle Scholar
  38. 38.
    Dong X, Qiu XS, Wang EH, Li QC, Gu W. [Expression of vascular endothelial growth factor (VEGF) C and VEGF receptor 3 in non-small cell lung cancer]. Zhonghua Bing Li Xue Za Zhi 2003, 32: 128–32.PubMedGoogle Scholar
  39. 39.
    Duff SE, Li C, Renehan A, O’Dwyer ST, Kumar S. Immunodetection and molecular forms of plasma vascular endothelial growth factor-C. Int J Oncol 2003, 22: 339–43.PubMedGoogle Scholar
  40. 40.
    Duff SE, Saunders M, McCredie V, et al. Pre-operative plasma levels of vascular endothelial growth factor A, C and D in patients with colorectal cancer. Clin Oncol (R Coll Radiol) 2005, 17: 367–71.Google Scholar
  41. 41.
    Duntas L, Grab-Duntas BM. Risk and prognostic factors for differentiated thyroid cancer. Hell J Nucl Med 2006, 9: 156–62.PubMedGoogle Scholar
  42. 42.
    Duque JL, Loughlin KR. An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. Urol Clin North Am 2000, 27: 125–35, X.PubMedCrossRefGoogle Scholar
  43. 43.
    Ennis RD, Petrylak DP, Singh P, et al. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer. J Urol 2000, 163: 1413–18.PubMedCrossRefGoogle Scholar
  44. 44.
    Evangelou E, Kyzas PA, Trikalinos TA. Comparison of the diagnostic accuracy of lymphatic endothelium markers: Bayesian approach. Mod Pathol 2005, 18: 1490–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Fellmer PT, Sato K, Tanaka R, et al. Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas. Surgery 1999, 126: 1056–61.PubMedCrossRefGoogle Scholar
  46. 46.
    Fogt F, Zimmerman RL, Ross HM, Daly T, Gausas RE. Identification of lymphatic vessels in malignant, adenomatous and normal colonic mucosa using the novel immunostain D2-40. Oncol Rep 2004, 11: 47–50.PubMedGoogle Scholar
  47. 47.
    Franchi A, Gallo O, Massi D, Baroni G, Santucci M. Tumor lymphangiogenesis in head and neck squamous cell carcinoma: a morphometric study with clinical correlations. Cancer 2004, 101: 973–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Frankel WL. Update on pancreatic endocrine tumors. Arch Pathol Lab Med 2006, 130: 963–6.PubMedGoogle Scholar
  49. 49.
    Fujimoto J, Toyoki H, Sato E, Sakaguchi H, Tamaya T. Clinical implication of expression of vascular endothelial growth factor-C in metastatic lymph nodes of uterine cervical cancers. Br J Cancer 2004, 91: 466–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Fuller CD, Wang SJ, Thomas CR, Jr., et al. Conditional survival in head and neck squamous cell carcinoma: results from the SEER dataset 1973–1998. Cancer 2007, 109: 1331–43.PubMedCrossRefGoogle Scholar
  51. 51.
    Funaki H, Nishimura G, Harada S, et al. Expression of vascular endothelial growth factor D is associated with lymph node metastasis in human colorectal carcinoma. Oncology 2003, 64: 416–22.PubMedCrossRefGoogle Scholar
  52. 52.
    Furudoi A, Tanaka S, Haruma K, et al. Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology 2002, 62: 157–66.PubMedCrossRefGoogle Scholar
  53. 53.
    George ML, Tutton MG, Janssen F, et al. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia 2001, 3: 420–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Giorgadze TA, Baloch ZW, Pasha T, Zhang PJ, Livolsi VA. Lymphatic and blood vessel density in the follicular patterned lesions of thyroid. Mod Pathol 2005, 18: 1424–31.PubMedCrossRefGoogle Scholar
  55. 55.
    Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005, 16: 1569–83.PubMedCrossRefGoogle Scholar
  56. 56.
    Gombos Z, Xu X, Chu CS, Zhang PJ, Acs G. Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix. Clin Cancer Res 2005, 11: 8364–71.PubMedCrossRefGoogle Scholar
  57. 57.
    Goydos JS, Gorski DH. Vascular endothelial growth factor C mRNA expression correlates with stage of progression in patients with melanoma. Clin Cancer Res 2003, 9: 5962–7.PubMedGoogle Scholar
  58. 58.
    Gunnigham SP, Currie MJ, Han C, et al. The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers. Clin Cancer Res 2000, 6: 4278–86.Google Scholar
  59. 59.
    Gunningham SP, Currie MJ, Han C, et al. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. Cancer Res 2001, 61: 3206–211.PubMedGoogle Scholar
  60. 60.
    Guo X, Chen L, Lang R, et al. Invasive micropapillary carcinoma of the breast: association of pathologic features with lymph node metastasis. Am J Clin Pathol 2006, 126: 740–6.PubMedCrossRefGoogle Scholar
  61. 61.
    Hall FT, Freeman JL, Asa SL, Jackson DG, Beasley NJ. Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2003, 129: 716–19.Google Scholar
  62. 62.
    Hall PN, Javaid M, de Takats PG. Therapeutic trends in cutaneous melanoma. Hosp Med 1999, 60: 39–3.PubMedGoogle Scholar
  63. 63.
    Hanrahan V, Currie MJ, Gunningham SP, et al. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol 2003, 200: 183–94.PubMedCrossRefGoogle Scholar
  64. 64.
    Hashimoto I, Kodama J, Seki N, et al. Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer. Br J Cancer 2001, 85: 93–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Heasley DD, Toda S, Mihm MC, Jr. Pathology of malignant melanoma. Surg Clin North Am 1996, 76: 1223–55.PubMedCrossRefGoogle Scholar
  66. 66.
    Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006, 20: 1218–49.PubMedCrossRefGoogle Scholar
  67. 67.
    Hinojar-Gutierrez A, Fernandez-Contreras ME, Gonzalez-Gonzalez R, et al. Intratumoral lymphatic vessels and VEGF-C expression are predictive factors of lymph node relapse in T1-T4 N0 laryngopharyngeal squamous cell carcinoma. Ann Surg Oncol 2007, 14: 248–57.PubMedCrossRefGoogle Scholar
  68. 68.
    Hoar FJ, Chaudhri S, Wadley MS, Stonelake PS. Co-expression of vascular endothelial growth factor C (VEGF-C) and c-erbB2 in human breast carcinoma. Eur J Cancer 2003, 39: 1698–703.PubMedCrossRefGoogle Scholar
  69. 69.
    Hsieh CY, Chen CA, Chou CH, et al. Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa B: implications for malignant ascites formation and tumor lymphangiogenesis. J Biomed Sci 2004, 11: 249–59.PubMedGoogle Scholar
  70. 70.
    Hu SE, Zhang YJ, Cui YM, Zhang HQ. [Expression of vascular endothelial growth factor A and C in human breast cancer and their significance]. Ai Zheng 2005, 24: 1076–9.PubMedGoogle Scholar
  71. 71.
    Hu WG, Li JW, Feng B, et al. Vascular endothelial growth factors C and D represent novel prognostic markers in colorectal carcinoma using quantitative image analysis. Eur Surg Res 2007, 39: 229–38.PubMedCrossRefGoogle Scholar
  72. 72.
    Huang JH, Li Y, Liu L, et al. [Lymphangiogenes and location of tumor lymphatic vessels induced by VEGF-C in primary breast carcer]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006, 31: 36–9, 51.PubMedGoogle Scholar
  73. 73.
    Hung CJ, Ginzinger DG, Zarnegar R, et al. Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors. J Clin Endocrinol Metab 2003, 88: 3694–99.PubMedCrossRefGoogle Scholar
  74. 74.
    Ichikura T, Tomimatsu S, Ohkura E, Mochizuki H. Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma. J Surg Oncol 2001, 78: 132–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Ishikawa Y, Akasaka Y, Kiguchi H, et al. The human renal lymphatics under normal and pathological conditions. Histopathology 2006, 49: 265–73.PubMedCrossRefGoogle Scholar
  76. 76.
    Jackson DG. Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis. APMIS 2004, 112: 526–38.PubMedCrossRefGoogle Scholar
  77. 77.
    Jennbacken K, Vallbo C, Wang W, Damber JE. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 2005, 65: 110–16.PubMedCrossRefGoogle Scholar
  78. 78.
    Jia YT, Li ZX, He YT, et al. Expression of vascular endothelial growth factor-C and the relationship between lymphangiogenesis and lymphatic metastasis in colorectal cancer. World J Gastroenterol 2004, 10: 3261–3.PubMedGoogle Scholar
  79. 79.
    Jiang HG, Gao M, Tang WP, Li FH, Cai QZ. [Expression and significance of VEGF, VEGF-C, and VEGF-D in papillary thyroid carcinoma]. Ai Zheng 2005, 24: 1136–9.PubMedGoogle Scholar
  80. 80.
    Johnson LA, Prevo R, Clasper S, Jackson DG. Inflammation-induced uptake and degradation of the lymphatic endothelial hyaluronan receptor lyve-1. J Biol Chem 2007, 282: 33671–80.PubMedCrossRefGoogle Scholar
  81. 81.
    Juttner S, Wissmann C, Jons T, et al. Vascular endothelial growth factor-d and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006, 24: 228–40.PubMedCrossRefGoogle Scholar
  82. 82.
    Kabashima A, Maehara Y, Kakeji Y, Sugimachi K. Overexpression of vascular endothelial growth factor C is related to lymphogenous metastasis in early gastric carcinoma. Oncology 2001, 60: 146–50.PubMedCrossRefGoogle Scholar
  83. 83.
    Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi’s sarcoma and a subset of angiosarcomas. Mod Pathol 2002, 15: 434–40.PubMedCrossRefGoogle Scholar
  84. 84.
    Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002, 82: 1255–7.PubMedGoogle Scholar
  85. 85.
    Kaio E, Tanaka S, Kitadai Y, et al. Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 2003, 64: 61–73.PubMedCrossRefGoogle Scholar
  86. 86.
    Kajita T, Ohta Y, Kimura K, et al. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer 2001, 85: 255–60.PubMedCrossRefGoogle Scholar
  87. 87.
    Kalady MF, White RR, Johnson JL, Tyler DS, Seigler HF. Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg 2003, 238: 528–35.PubMedGoogle Scholar
  88. 88.
    Kato T, Prevo R, Steers G, et al. A quantitative analysis of lymphatic vessels in human breast cancer, based on LYVE-1 immunoreactivity. Br J Cancer 2005, 93: 1168–74.PubMedCrossRefGoogle Scholar
  89. 89.
    Kaushal V, Mukunyadzi P, Dennis RA, et al. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Clin Cancer Res 2005, 11: 584–93.PubMedGoogle Scholar
  90. 90.
    Kawakami M, Furuhata T, Kimura Y, et al. Expression analysis of vascular endothelial growth factors and their relationships to lymph node metastasis in human colorectal cancer. J Exp Clin Cancer Res 2003, 22: 229–37.PubMedGoogle Scholar
  91. 91.
    Kawakami M, Furuhata T, Kimura Y, et al. Quantification of vascular endothelial growth factor-C and its receptor-3 messenger RNA with real-time quantitative polymerase chain reaction as a predictor of lymph node metastasis in human colorectal cancer. Surgery 2003, 133: 300–8.PubMedCrossRefGoogle Scholar
  92. 92.
    Kazama S, Kitayama J, Watanabe T, Nagawa H. Expression pattern of vascular endothelial growth factor-C in human colorectal normal mucosa and neoplastic mucosa. Hepatogastroenterology 2004, 51: 391–5.PubMedGoogle Scholar
  93. 93.
    Kazama S, Watanabe T, Kanazawa T, Hatano K, Nagawa H. Vascular endothelial growth factor-C (VEGF-C) is a more specific risk factor for lymph node metastasis than VEGF-D in submucosal colorectal cancer. Hepatogastroenterology 2007, 54: 71–6.PubMedGoogle Scholar
  94. 94.
    Kimura Y, Watanabe M, Ohga T, et al. Vascular endothelial growth factor C expression correlates with lymphatic involvement and poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep 2003, 10: 1747–51.PubMedGoogle Scholar
  95. 95.
    Kinoshita J, Kitamura K, Kabashima A, et al. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat 2001, 66: 159–64.PubMedCrossRefGoogle Scholar
  96. 96.
    Kitadai Y, Amioka T, Haruma K, et al. Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer 2001, 93: 662–6.PubMedCrossRefGoogle Scholar
  97. 97.
    Kitadai Y, Kodama M, Cho S, et al. Quantitative analysis of lymphangiogenic markers for predicting metastasis of human gastric carcinoma to lymph nodes. Int J Cancer 2005, 115: 388–92.PubMedCrossRefGoogle Scholar
  98. 98.
    Kleespies A, Bruns CJ, Jauch KW. Clinical significance of VEGF-A, -C and -D expression in esophageal malignancies. Onkologie 2005, 28: 281–8.PubMedCrossRefGoogle Scholar
  99. 99.
    Kojima H, Shijubo N, Yamada G, et al. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer 2005, 104: 1668–77.PubMedCrossRefGoogle Scholar
  100. 100.
    Koukourakis MI, Giatromanolaki A, Sivridis E, et al. LYVE-1 immunohistochemical assessment of lymphangiogenesis in endometrial and lung cancer. J Clin Pathol 2005, 58: 202–6.PubMedCrossRefGoogle Scholar
  101. 101.
    Krzystek-Korpacka M, Matusiewicz M, Diakowska D, et al. Up-regulation of VEGF-C secreted by cancer cells and not VEGF-A correlates with clinical evaluation of lymph node metastasis in esophageal squamous cell carcinoma (ESCC). Cancer Lett 2007, 249: 171–7.PubMedCrossRefGoogle Scholar
  102. 102.
    Kubo H, Fujiwara T, Jussila L, et al. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood 2000, 96: 546–53.PubMedGoogle Scholar
  103. 103.
    Kurahara H, Takao S, Maemura K, et al. Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis. Clin Cancer Res 2004, 10: 8413–20.PubMedCrossRefGoogle Scholar
  104. 104.
    Kurebayashi J, Otsuki T, Kunisue H, et al. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res 1999, 90: 977–81.PubMedGoogle Scholar
  105. 105.
    Kuroyama S, Kobayashi N, Ohbu M, et al. Enzyme histochemical analysis of lymphatic vessels in colon carcinoma: occurrence of lymphangiogenesis within the tumor. Hepatogastroenterology 2005, 52: 1057–61.PubMedGoogle Scholar
  106. 106.
    Kyzas PA, Geleff S, Batistatou A, Agnantis NJ, Stefanou D. Evidence for lymphangiogenesis and its prognostic implications in head and neck squamous cell carcinoma. J Pathol 2005, 206: 170–7.PubMedCrossRefGoogle Scholar
  107. 107.
    Kyzas PA, Stefanou D, Agnantis NJ. COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma. Mod Pathol 2005, 18: 153–60.PubMedCrossRefGoogle Scholar
  108. 108.
    Lerner SP, Skinner E, Skinner DG. Radical cystectomy in regionally advanced bladder cancer. Urol Clin North Am 1992, 19: 713–23.PubMedGoogle Scholar
  109. 109.
    Li J, Hong M, Pan T. Clinical significance of VEGF-C and VEGFR-3 expression in non-small cell lung cancer. J Huazhong Univ Sci Technolog Med Sci 2006, 26: 587–90.PubMedCrossRefGoogle Scholar
  110. 110.
    Li Q, Dong X, Gu W, Qiu X, Wang E. Clinical significance of co-expression of VEGF-C and VEGFR-3 in non-small cell lung cancer. Chin Med J (Engl) 2003, 116: 727–30.Google Scholar
  111. 111.
    Li QL, Chen FJ, Zeng ZY, et al. [Expression and clinical significance of VEGF-C and Flt-4 in tongue squamous cell carcinoma]. Ai Zheng 2006, 25: 235–40.PubMedGoogle Scholar
  112. 112.
    Li R, Younes M, Wheeler TM, et al. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate 2004, 58: 193–9.PubMedCrossRefGoogle Scholar
  113. 113.
    Liang P, Hong JW, Ubukata H, et al. Increased density and diameter of lymphatic microvessels correlate with lymph node metastasis in early stage invasive colorectal carcinoma. Virchows Arch 2006, 448: 570–5.PubMedCrossRefGoogle Scholar
  114. 114.
    Liang QC, Wei QY, Fan SQ. [Expression of VEGF-C and angiogenesis, and lymphangiogenesis in papillary thyroid carcinoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006, 31: 414–6, 419.PubMedGoogle Scholar
  115. 115.
    Liu F, Zhang YJ. [Roles of VEGF-C and its receptor Flt-4 in proliferation and metastasis of primary breast cancer]. Ai Zheng 2003, 22: 1053–56.PubMedGoogle Scholar
  116. 116.
    Loeb S, Roehl KA, Yu X, et al. Lymphovascular invasion in radical prostatectomy specimens: prediction of adverse pathologic features and biochemical progression. Urology 2006, 68: 99–103.PubMedCrossRefGoogle Scholar
  117. 117.
    Loges S, Clausen H, Reichelt U, et al. Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasis. Clin Cancer Res 2007, 13: 76–80.PubMedCrossRefGoogle Scholar
  118. 118.
    Maeda K, Yashiro M, Nishihara T, et al. Correlation between vascular endothelial growth factor C expression and lymph node metastasis in T1 carcinoma of the colon and rectum. Surg Today 2003, 33: 736–39.PubMedCrossRefGoogle Scholar
  119. 119.
    Massi D, Puig S, Franchi A, et al. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study. J Clin Pathol 2006, 59: 166–73.PubMedCrossRefGoogle Scholar
  120. 120.
    Mathur SP, Mathur RS, Gray EA, et al. Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-B. Gynecol Oncol 2005, 98: 467–83.PubMedCrossRefGoogle Scholar
  121. 121.
    Matsumoto K, Nakayama Y, Inoue Y, et al. Lymphatic microvessel density is an independent prognostic factor in colorectal cancer. Dis Colon Rectum 2007, 50: 308–14.PubMedCrossRefGoogle Scholar
  122. 122.
    Matsumoto M, Natsugoe S, Okumura H, et al. Overexpression of vascular endothelial growth factor-C correlates with lymph node micrometastasis in submucosal esophageal cancer. J Gastrointest Surg 2006, 10: 1016–22.PubMedCrossRefGoogle Scholar
  123. 123.
    Matsuyama H, Hirata H, Korenaga Y, et al. Clinical significance of lymph node dissection in renal cell carcinoma. Scand J Urol Nephrol 2005, 39: 30–5.PubMedCrossRefGoogle Scholar
  124. 124.
    Maula SM, Luukkaa M, Grenman R, et al. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 2003, 63: 1920–26.PubMedGoogle Scholar
  125. 125.
    May M, Kaufmann O, Hammermann F, Loy V, Siegsmund M. Prognostic impact of lymphovascular invasion in radical prostatectomy specimens. BJU Int 2007, 99: 539–44.PubMedCrossRefGoogle Scholar
  126. 126.
    McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 2004, 119: 174–86.PubMedGoogle Scholar
  127. 127.
    Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002, 147: 62–70.PubMedCrossRefGoogle Scholar
  128. 128.
    Metts MC, Metts JC, Milito SJ, Thomas CR, Jr. Bladder cancer: a review of diagnosis and management. J Natl Med Assoc 2000, 92: 285–94.PubMedGoogle Scholar
  129. 129.
    Minervini A, Lilas L, Morelli G, et al. Regional lymph node dissection in the treatment of renal cell carcinoma: is it useful in patients with no suspected adenopathy before or during surgery? BJU Int 2001, 88: 169–72.PubMedCrossRefGoogle Scholar
  130. 130.
    Mitsuhashi A, Suzuka K, Yamazawa K, et al. Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. Cancer 2005, 103: 724–30.PubMedCrossRefGoogle Scholar
  131. 131.
    Miyata Y, Kanda S, Ohba K, et al. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D. Clin Cancer Res 2006, 12: 800–6.PubMedCrossRefGoogle Scholar
  132. 132.
    Mobius C, Freire J, Becker I, et al. VEGF-C expression in squamous cell carcinoma and adenocarcinoma of the esophagus. World J Surg 2007, 31: 1768–74.PubMedCrossRefGoogle Scholar
  133. 133.
    Mohammed RA, Green A, El Shikh S, et al. Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer 2007, 96: 1092–100.PubMedCrossRefGoogle Scholar
  134. 134.
    Mori D, Yamasaki F, Shibaki M, Tokunaga O. Lateral peritumoral lymphatic vessel invasion can predict lymph node metastasis in esophageal squamous cell carcinoma. Mod Pathol 2007, 20: 694–700.PubMedCrossRefGoogle Scholar
  135. 135.
    Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992, 127: 392–9.PubMedGoogle Scholar
  136. 136.
    Mou JH, Yan XC, Li ZP, et al. [Characteristic and clinicopathologic significance of lymphangiogenesis in colorectal cancer]. Zhonghua Bing Li Xue Za Zhi 2005, 34: 348–52.PubMedGoogle Scholar
  137. 137.
    Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997, 111: 1710–17.PubMedCrossRefGoogle Scholar
  138. 138.
    Mountain CF. The international system for staging lung cancer. Semin Surg Oncol 2000, 18: 106–15.PubMedCrossRefGoogle Scholar
  139. 139.
    Mouta CC, Nasser SM, di Tomaso E, et al. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res 2001, 61: 8079–84.Google Scholar
  140. 140.
    Munoz-Guerra MF, Marazuela EG, Martin-Villar E, Quintanilla M, Gamallo C. Prognostic significance of intratumoral lymphangiogenesis in squamous cell carcinoma of the oral cavity. Cancer 2004, 100: 553–60.PubMedCrossRefGoogle Scholar
  141. 141.
    Nagakawa T, Konishi I, Higashino Y, et al. The spread and prognosis of carcinoma in the region of the pancreatic head. Jpn J Surg 1989, 19: 510–18.PubMedCrossRefGoogle Scholar
  142. 142.
    Nakamura Y, Yasuoka H, Tsujimoto M, et al. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat 2005, 91: 125–32.PubMedCrossRefGoogle Scholar
  143. 143.
    Nakamura Y, Yasuoka H, Tsujimoto M, et al. Importance of lymph vessels in gastric cancer: a prognostic indicator in general and a predictor for lymph node metastasis in early stage cancer. J Clin Pathol 2006, 59: 77–82.PubMedCrossRefGoogle Scholar
  144. 144.
    Nakamura Y, Yasuoka H, Zuo H, et al. Nitric oxide in papillary thyroid carcinoma: induction of vascular endothelial growth factor D and correlation with lymph node metastasis. J Clin Endocrinol Metab 2006, 91: 1582–5.PubMedCrossRefGoogle Scholar
  145. 145.
    Nakamura Y, Yasuoka H, Tsujimoto M, et al. Flt-4-Positive vessel density correlates with vascular endothelial growth factor-D expression, nodal status, and prognosis in breast cancer. Clin Cancer Res 2003, 9: 5313–17.PubMedGoogle Scholar
  146. 146.
    Nakayama Y, Matsumoto K, Nagato M, et al. Significance of lymphangiogenesis as assessed by immunohistochemistry for podoplanin in patients with esophageal carcinoma. Anticancer Res 2007, 27: 619–25.PubMedGoogle Scholar
  147. 147.
    Niakosari F, Kahn HJ, Marks A, From L. Detection of lymphatic invasion in primary melanoma with monoclonal antibody D2-40: a new selective immunohistochemical marker of lymphatic endothelium. Arch Dermatol 2005, 141: 440–44.PubMedCrossRefGoogle Scholar
  148. 148.
    Niki T, Iba S, Tokunou M, et al. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 2000, 6: 2431–9.PubMedGoogle Scholar
  149. 149.
    Noguchi T, Takeno S, Shibata T, et al. VEGF-C expression correlates with histological differentiation and metastasis in squamous cell carcinoma of the esophagus. Oncol Rep 2002, 9: 995–9.PubMedGoogle Scholar
  150. 150.
    Obermair A, Wanner C, Bilgi S, et al. Tumor angiogenesis in stage IB cervical cancer: correlation of microvessel density with survival. Am J Obstet Gynecol 1998, 178: 314–19.PubMedCrossRefGoogle Scholar
  151. 151.
    Ogawa E, Takenaka K, Yanagihara K, et al. Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non-small cell lung cancer patients. Br J Cancer 2004, 91: 498–503.PubMedCrossRefGoogle Scholar
  152. 152.
    Ohta Y, Nozawa H, Tanaka Y, Oda M, Watanabe Y. Increased vascular endothelial growth factor and vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2000, 119: 804–13.PubMedCrossRefGoogle Scholar
  153. 153.
    Okada K, Osaki M, Araki K, et al. Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas. Anticancer Res 2005, 25: 3003–9.PubMedGoogle Scholar
  154. 154.
    Omachi T, Kawai Y, Mizuno R, et al. Immunohistochemical demonstration of proliferating lymphatic vessels in colorectal carcinoma and its clinicopathological significance. Cancer Lett 2007, 246: 167–72.PubMedCrossRefGoogle Scholar
  155. 155.
    Ono H, Kondo H, Gotoda T, et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut 2001, 48: 225–9.PubMedCrossRefGoogle Scholar
  156. 156.
    Onogawa S, Kitadai Y, Amioka T, et al. Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in early gastric carcinoma: correlation with clinicopathological parameters. Cancer Lett 2005, 226: 85–90.PubMedCrossRefGoogle Scholar
  157. 157.
    Onogawa S, Kitadai Y, Tanaka S, et al. Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci 2004, 95: 32–9.PubMedCrossRefGoogle Scholar
  158. 158.
    Pang XH, Tian H, Liu ZY, et al. [Significance and expression of vascular endothelial growth factor-C (VEGF-C) in esophageal squamous carcinoma and glioma]. Ai Zheng 2003, 22: 1166–9.PubMedGoogle Scholar
  159. 159.
    Parr C, Jiang WG. Quantitative analysis of lymphangiogenic markers in human colorectal cancer. Int J Oncol 2003, 23: 533–9.PubMedGoogle Scholar
  160. 160.
    Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 1999, 86: 2406–12.PubMedCrossRefGoogle Scholar
  161. 161.
    Pepper MS, Tille JC, Nisato R, Skobe M. Lymphangiogenesis and tumor metastasis. Cell Tissue Res 2003, 314: 167–77.PubMedCrossRefGoogle Scholar
  162. 162.
    Quon H, Liu FF, Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001, 23: 147–59.PubMedCrossRefGoogle Scholar
  163. 163.
    Renyi-Vamos F, Tovari J, Fillinger J, et al. Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res 2005, 11: 7344–53.PubMedCrossRefGoogle Scholar
  164. 164.
    Roma AA, Magi-Galluzzi C, Kral MA, et al. Peritumoral lymphatic invasion is associated with regional lymph node metastases in prostate adenocarcinoma. Mod Pathol 2006, 19: 392–8.PubMedCrossRefGoogle Scholar
  165. 165.
    Rubbia-Brandt L, Terris B, Giostra E, et al. Lymphatic vessel density and vascular endothelial growth factor-C expression correlate with malignant behavior in human pancreatic endocrine tumors. Clin Cancer Res 2004, 10: 6919–28.PubMedCrossRefGoogle Scholar
  166. 166.
    Saad RS, Kordunsky L, Liu YL, et al. Lymphatic microvessel density as prognostic marker in colorectal cancer. Mod Pathol 2006, 19: 1317–23.PubMedCrossRefGoogle Scholar
  167. 167.
    Salven P, Lymboussaki A, Heikkila P, et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 1998, 153: 103–8.PubMedGoogle Scholar
  168. 168.
    Schacht V, Dadras SS, Johnson LA, et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005, 166: 913–21.PubMedGoogle Scholar
  169. 169.
    Schietroma C, Cianfarani F, Lacal PM, et al. Vascular endothelial growth factor-C expression correlates with lymph node localization of human melanoma metastases. Cancer 2003, 98: 789–97.PubMedCrossRefGoogle Scholar
  170. 170.
    Schmelz M, Franke WW. Complexus adhaerentes, a new group of desmoplakin-containing junctions in endothelial cells: the syndesmos connecting retothelial cells of lymph nodes. Eur J Cell Biol 1993, 61: 274–89.PubMedGoogle Scholar
  171. 171.
    Schneider M, Buchler P, Giese N, et al. Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread. Int J Oncol 2006, 28: 883–90.PubMedGoogle Scholar
  172. 172.
    Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004, 240: 306–12.PubMedCrossRefGoogle Scholar
  173. 173.
    Schoppmann SF, Schindl M, Breiteneder-Geleff S, et al. Inflammatory stromal reaction correlates with lymphatic microvessel density in early-stage cervival cancer. Anticancer Res 2001, 21: 3419–23.PubMedGoogle Scholar
  174. 174.
    Schoppmann SF, Birner P, Stockl J, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002, 161: 947–56.PubMedGoogle Scholar
  175. 175.
    Shida A, Fujioka S, Ishibashi Y, et al. Prognostic significance of vascular endothelial growth factor D in gastric carcinoma. World J Surg 2005, 29: 1600–607.PubMedCrossRefGoogle Scholar
  176. 176.
    Shields JD, Borsetti M, Rigby H, et al. Lymphatic density and metastatic spread in human malignant melanoma. Br J Cancer 2004, 90: 693–700.PubMedCrossRefGoogle Scholar
  177. 177.
    Shimizu K, Kubo H, Yamaguchi K, et al. Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci 2004, 95: 328–33.PubMedCrossRefGoogle Scholar
  178. 178.
    Sipos B, Klapper W, Kruse ML, et al. Expression of lymphangiogenic factors and evidence of intratumoral lymphangiogenesis in pancreatic endocrine tumors. Am J Pathol 2004, 165: 1187–97.PubMedGoogle Scholar
  179. 179.
    Sipos B, Kojima M, Tiemann K, et al. Lymphatic spread of ductal pancreatic adenocarcinoma is independent of lymphangiogenesis. J Pathol 2005, 207: 301–12.PubMedCrossRefGoogle Scholar
  180. 180.
    Sleeman JP, Krishnan J, Kirkin V, Baumann P. Markers for the lymphatic endothelium: in search of the holy grail? Microsc Res Tech 2001, 55: 61–9.PubMedCrossRefGoogle Scholar
  181. 181.
    Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 2006, 56: 168–83.PubMedCrossRefGoogle Scholar
  182. 182.
    Soumaoro LT, Uetake H, Takagi Y, et al. Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis. Dis Colon Rectum 2006, 49: 392–8.PubMedCrossRefGoogle Scholar
  183. 183.
    Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002, 2: 573–83.PubMedCrossRefGoogle Scholar
  184. 184.
    Stearns ME, Wang M, Hu Y, Kim G, Garcia FU. Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis. Lab Invest 2004, 84: 785–95.PubMedCrossRefGoogle Scholar
  185. 185.
    Stessels F, Van den Eynden G, Van der Auwera I, et al. Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer 2004, 90: 1429–36.PubMedCrossRefGoogle Scholar
  186. 186.
    Straume O, Jackson DG, Akslen LA. Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res 2003, 9: 250–6.PubMedGoogle Scholar
  187. 187.
    Sturgeon C, Angelos P. Identification and treatment of aggressive thyroid cancers. Part 1: subtypes. Oncology (Williston Park) 2006, 20: 253–60.Google Scholar
  188. 188.
    Sundar SS, Zhang H, Brown P, et al. Role of lymphangiogenesis in epithelial ovarian cancer. Br J Cancer 2006, 94: 1650–7.PubMedGoogle Scholar
  189. 189.
    Suzuki K, Morita T, Tokue A. Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. Int J Urol 2005, 12: 152–8.PubMedCrossRefGoogle Scholar
  190. 190.
    Takahashi A, Kono K, Itakura J, et al. Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer. Oncology 2002, 62: 121–7.PubMedCrossRefGoogle Scholar
  191. 191.
    Takizawa H, Kondo K, Fujino H, et al. The balance of VEGF-C and VEGFR-3 mRNA is a predictor of lymph node metastasis in non-small cell lung cancer. Br J Cancer 2006, 95: 75–9.PubMedCrossRefGoogle Scholar
  192. 192.
    Tamura M, Oda M, Matsumoto I, et al. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer. Ann Surg Oncol 2004, 11: 928–33.PubMedCrossRefGoogle Scholar
  193. 193.
    Tamura M, Ohta Y. Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis. Cancer 2003, 98: 1217–22.PubMedCrossRefGoogle Scholar
  194. 194.
    Tamura M, Oda M, Tsunezuka Y, et al. Chest CT and serum vascular endothelial growth factor-C level to diagnose lymph node metastasis in patients with primary non-small cell lung cancer. Chest 2004, 126: 342–6.PubMedCrossRefGoogle Scholar
  195. 195.
    Tanaka K, Kurebayashi J, Sonoo H, et al. Expression of vascular endothelial growth factor family messenger RNA in diseased thyroid tissues. Surg Today 2002, 32: 761–8.PubMedCrossRefGoogle Scholar
  196. 196.
    Tang RF, Wang SX, Peng L, et al. Expression of vascular endothelial growth factors A and C in human pancreatic cancer. World J Gastroenterol 2006, 12: 280–6.PubMedGoogle Scholar
  197. 197.
    Tezuka K, Onoda N, Takashima T, et al. Prognostic significance of lymphovascular invasion diagnosed by lymphatic endothelium immunostaining in breast cancer patients. Oncol Rep 2007, 17: 997–1003.PubMedGoogle Scholar
  198. 198.
    Tiffen J, Mahon SM. Cervical cancer: what should we tell women about screening? Clin J Oncol Nurs 2006, 10: 527–31.PubMedCrossRefGoogle Scholar
  199. 199.
    Trojan L, Michel MS, Rensch F, et al. Lymph and blood vessel architecture in benign and malignant prostatic tissue: lack of lymphangiogenesis in prostate carcinoma assessed with novel lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE-1). J Urol 2004, 172: 103–7.PubMedCrossRefGoogle Scholar
  200. 200.
    Trojan L, Rensch F, Voss M, et al. The role of the lymphatic system and its specific growth factor, vascular endothelial growth factor C, for lymphogenic metastasis in prostate cancer. BJU Int 2006, 98: 903–6.PubMedCrossRefGoogle Scholar
  201. 201.
    Tsai CS, Lai CH, Wang CC, et al. The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy. Gynecol Oncol 1999, 75: 328–33.PubMedCrossRefGoogle Scholar
  202. 202.
    Tsuchiya N, Sato K, Akao T, et al. Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma. Tohoku J Exp Med 2001, 195: 101–13.PubMedCrossRefGoogle Scholar
  203. 203.
    Tsurusaki T, Kanda S, Sakai H, et al. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer 1999, 80: 309–13.PubMedCrossRefGoogle Scholar
  204. 204.
    Ueda M, Hung YC, Terai Y, et al. Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas. Clin Cancer Res 2005, 11: 3225–32.PubMedCrossRefGoogle Scholar
  205. 205.
    Ueda M, Terai Y, Yamashita Y, et al. Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomas. Int J Cancer 2002, 98: 335–43.PubMedCrossRefGoogle Scholar
  206. 206.
    Vallbohmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus 2006, 19: 425–32.PubMedCrossRefGoogle Scholar
  207. 207.
    Valtola R, Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999, 154: 1381–90.PubMedGoogle Scholar
  208. 208.
    Van Dam PA, Hauspy J, Vanderheyden T, et al. Intraoperative sentinel node identification with Technetium-99 m-labeled nanocolloid in patients with cancer of the uterine cervix: a feasibility study. Int J Gynecol Cancer 2003, 13: 182–6.PubMedCrossRefGoogle Scholar
  209. 209.
    Van den Eynden GG, Van der Auwera I, Van Laere SJ, et al. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer 2006, 94: 1643–9.PubMedGoogle Scholar
  210. 210.
    Van den Eynden GG, Van der Auwerra I, Van Laere SJ, et al. Induction of lymphangiogenesis in and around axillary lymph node metastases of patients with breast cancer. Br J Cancer 2006, 95: 1362–6.PubMedCrossRefGoogle Scholar
  211. 211.
    Van der Auwera I, Cao Y, Tille JC, et al. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer 2006, 95: 1611–25.PubMedCrossRefGoogle Scholar
  212. 212.
    Van der Auwera I, Van den Eynden GG, Colpaert CG, et al. Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin Cancer Res 2005, 11: 7637–42.PubMedCrossRefGoogle Scholar
  213. 213.
    Van der Auwera I, Van Laere SJ, Van den Eynden GG, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 2004, 10: 7965–71.PubMedCrossRefGoogle Scholar
  214. 214.
    Van der Schaft DW, Pauwels P, Hulsmans S, et al. Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer Lett 2007, 256: 279–81.CrossRefGoogle Scholar
  215. 215.
    Van Trappen PO, Steele D, Lowe DG, et al. Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 2003, 201: 544–54.PubMedCrossRefGoogle Scholar
  216. 216.
    Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002, 38: 1564–79.PubMedCrossRefGoogle Scholar
  217. 217.
    Vleugel MM, Bos R, Van der Groep P, et al. Lack of lymphangiogenesis during breast carcinogenesis. J Clin Pathol 2004, 57: 746–51.PubMedCrossRefGoogle Scholar
  218. 218.
    Waggoner SE. Cervical cancer. Lancet 2003, 361: 2217–25.PubMedCrossRefGoogle Scholar
  219. 219.
    Walgenbach-Bruenagel G, Tolba RH, Varnai AD, et al. Detection of lymphatic invasion in early stage primary colorectal cancer with the monoclonal antibody D2-40. Eur Surg Res 2006, 38: 438–44.PubMedCrossRefGoogle Scholar
  220. 220.
    Wang TB, Deng MH, Qiu WS, Dong WG. Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol 2007, 13: 1794–97.PubMedGoogle Scholar
  221. 221.
    Wang TB, Huang YH, Lan P, Song XM, Wang JP. [Correlation of lymphangiogenesis to progression of colorectal cancer]. Ai Zheng 2005, 24: 1276–79.PubMedGoogle Scholar
  222. 222.
    Wang Y, Sun JG, Ye MF, Chen ZT. [Clinical and prognostic significance of podoplanin-positive lymphatic vessel density in non-small cell lung carcinoma]. Zhonghua Jie He He Hu Xi Za Zhi 2006, 29: 758–61.PubMedGoogle Scholar
  223. 223.
    Warburton G, Nikitakis NG, Roberson P, et al. Histopathological and lymphangiogenic parameters in relation to lymph node metastasis in early stage oral squamous cell carcinoma. J Oral Maxillofac Surg 2007, 65: 475–84.PubMedCrossRefGoogle Scholar
  224. 224.
    Weich HA, Bando H, Brokelmann M, et al. Quantification of vascular endothelial growth factor-C (VEGF-C) by a novel ELISA. J Immunol Methods 2004, 285: 145–55.PubMedCrossRefGoogle Scholar
  225. 225.
    Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis – correlation in invasive breast carcinoma. N Engl J Med 1991, 324: 1–8.PubMedGoogle Scholar
  226. 226.
    Wetterwald A, Hoffstetter W, Cecchini MG, et al. Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone 1996, 18: 125–32.PubMedCrossRefGoogle Scholar
  227. 227.
    White JD, Hewett PW, Kosuge D, et al. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res 2002, 62: 1669–75.PubMedGoogle Scholar
  228. 228.
    Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999, 98: 769–78.PubMedCrossRefGoogle Scholar
  229. 229.
    Williams CS, Leek RD, Robson AM, et al. Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol 2003, 200: 195–206.PubMedCrossRefGoogle Scholar
  230. 230.
    Witte D, Thomas A, Ali N, Carlson N, Younes M. Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res 2002, 22: 1463–6.PubMedGoogle Scholar
  231. 231.
    Xu T, Chen D. Serum vascular endothelial growth factor-C and vascular endothelial growth factor level in patients with colorectal carcinoma and clinical significance. J Huazhong Univ Sci Technolog Med Sci 2006, 26: 329–31, 355.PubMedGoogle Scholar
  232. 232.
    Xu T, Chen D, Chen J. Expression of vascular endothelial growth factor C and its correlation with lymph node metastasis in colorectal carcinoma. J Huazhong Univ Sci Technolog Med Sci 2004, 24: 596–8.PubMedGoogle Scholar
  233. 233.
    Yamaguchi R, Yano H, Nakashima O, et al. Expression of vascular endothelial growth factor-C in human hepatocellular carcinoma. J Gastroenterol Hepatol 2006, 21: 152–60.PubMedCrossRefGoogle Scholar
  234. 234.
    Yamao T, Shirao K, Ono H, et al. Risk factors for lymph node metastasis from intramucosal gastric carcinoma. Cancer 1996, 77: 602–6.PubMedCrossRefGoogle Scholar
  235. 235.
    Yang J, Wu HF, Qian LX, et al. Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression. Asian J Androl 2006, 8: 169–75.PubMedCrossRefGoogle Scholar
  236. 236.
    Yang W, Klos K, Yang Y, et al. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 2002, 94: 2855–61.PubMedCrossRefGoogle Scholar
  237. 237.
    Yasuoka H, Nakamura Y, Zuo H, et al. VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Mod Pathol 2005, 18: 1127–33.PubMedCrossRefGoogle Scholar
  238. 238.
    Yokoyama Y, Charnock-Jones DS, Licence D, et al. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer 2003, 88: 237–44.PubMedCrossRefGoogle Scholar
  239. 239.
    Yonemura Y, Endo Y, Fujita H, et al. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 1999, 5: 1823–9.PubMedGoogle Scholar
  240. 240.
    Yonemura Y, Fushida S, Bando E, et al. Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. Eur J Cancer 2001, 37: 918–23.PubMedCrossRefGoogle Scholar
  241. 241.
    Yu XM, Lo CY, Chan WF, et al. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin Cancer Res 2005, 11: 8063–9.PubMedCrossRefGoogle Scholar
  242. 242.
    Yuanming L, Feng G, Lei T, Ying W. Quantitative analysis of lymphangiogenic markers in human gastroenteric tumor. Arch Med Res 2007, 38: 106–12.PubMedCrossRefGoogle Scholar
  243. 243.
    Zeng Y, Opeskin K, Baldwin ME, et al. Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res 2004, 10: 5137–44.PubMedCrossRefGoogle Scholar
  244. 244.
    Zeng Y, Opeskin K, Horvath LG, Sutherland RL, Williams ED. Lymphatic vessel density and lymph node metastasis in prostate cancer. Prostate 2005, 65: 222–30.PubMedCrossRefGoogle Scholar
  245. 245.
    Zhang GH, Zeng Y, Yang WT, Shi DR. [Study of mRNA expression of vascular endothelial growth factor-(A, C, D) genes and its effect on prognosis of breast cancer]. Zhonghua Bing Li Xue Za Zhi 2006, 35: 473–7.PubMedGoogle Scholar
  246. 246.
    Zhang HZ, Wei YP, Li HG, et al. [Expressions of vascular endothelial growth factor C and matrix metalloproteinases-2 and prognosis of non-small cell lung carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao 2006, 26: 1307–10.PubMedGoogle Scholar
  247. 247.
    Zu X, Tang Z, Li Y, et al. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int 2006, 98: 1090–3.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  1. 1.Translational Cancer Research Group, Laboratory of PathologyUniversity of Antwerp/University Hospital AntwerpAntwerpBelgium
  2. 2.Oncology Centre, General Hospital Sint-AugustinusWilrijkBelgium

Personalised recommendations